ABSTRACT Background: Few well-controlled studies have comprehensively examined the effects of very-low-carbohydrate diets on type 2 diabetes (T2D). Objective: We compared the effects of a very-low-carbohydrate, high-unsaturated fat, low-saturated fat (LC) diet with a highcarbohydrate, low-fat (HC) diet on glycemic control and cardiovascular disease risk factors in T2D after 52 wk. Design: In this randomized controlled trial that was conducted in an outpatient research clinic, 115 obese adults with T2D [mean 6 SD age: 58 6 7 y; body mass index (in kg/m 2 ): 34.6 6 4.3; glycated hemoglobin (HbA1c): 7.3 6 1.1%; duration of diabetes: 8 6 6 y] were randomly assigned to consume either a hypocaloric LC diet [14% of energy as carbohydrate (carbohydrate ,50 g/d), 28% of energy as protein, and 58% of energy as fat (,10% saturated fat)] or an energymatched HC diet [53% of energy as carbohydrate, 17% of energy as protein, and 30% of energy as fat (,10% saturated fat)] combined with supervised aerobic and resistance exercise (60 min; 3 d/wk). Outcomes were glycemic control assessed with use of measurements of HbA1c, fasting blood glucose, glycemic variability assessed with use of 48-h continuous glucose monitoring, diabetes medication, weight, blood pressure, and lipids assessed at baseline, 24, and 52 wk. Conclusions: Both diets achieved substantial weight loss and reduced HbA1c and fasting glucose. The LC diet, which was high in unsaturated fat and low in saturated fat, achieved greater improvements in the lipid profile, blood glucose stability, and reductions in diabetes medication requirements, suggesting an effective strategy for the optimization of T2D management. This trial was registered at www.anzctr.org.au as ACTRN12612000369820.
INTRODUCTION
Effective strategies are urgently needed to combat the global diabetes epidemic. A dietary intervention is a cornerstone of diabetes management with guidelines indicating dietary patterns varying in macronutrient composition may offer individualized approaches for treatment (1) . However, the efficacy of various diets is an important consideration in guiding clinical practice. Specifically, very-low-carbohydrate, high-fat diets have become popular but few well-controlled studies have comprehensively examined their long-term effects on glycemic control and cardiovascular disease (CVD) 11 risk in type 2 diabetes (T2D). This lack of research has precluded health authorities from making conclusive recommendations regarding the use of very-lowcarbohydrate diets for T2D management (1) .
Very-low-carbohydrate diets that typically replace carbohydrate with fat are often criticized for increasing saturated fat, which elevates LDL cholesterol, which is a primary CVD risk target (2, 3) . Metaanalyses of previous trials have suggested that very-low-carbohydrate diets promote less-favorable LDL cholesterol responses than do traditional high-carbohydrate, low-fat (HC) diets (4, 5) . Previous studies have also limited the assessment of glycemic control to glycated hemoglobin (HbA1c) (6) (7) (8) (9) (10) (11) ; frequently without an objective quantification of diabetes medication changes or the assessment of glycemic variability (GV), which is an emerging independent risk factor for diabetes-related complications (12, 13) . Moreover, verylow-carbohydrate diets have typically been assessed without the inclusion or control of physical activity as part of a comprehensive lifestyle-modification program (6) (7) (8) (9) 11) . Previous studies have also examined the effects of very-low-carbohydrate diets by using ad libitum approaches (6) (7) (8) (9) (10) (11) . Consequently, differences in energy intake and weight loss between comparison diets limit the understanding of the metabolic efficacy of different dietary approaches.
We recently reported, in obese adults with T2D, that a lifestylemodification program that incorporated a very-low-carbohydrate, high-unsaturated fat/low-saturated fat (LC) diet achieved greater reductions in HbA1c, GV, diabetes medication requirements, and improvements in the blood lipid profile (greater reductions in triglycerides and increases in HDL cholesterol without any detrimental effect on LDL cholesterol) than did an energy-matched HC diet after 24 wk (14) . In the current study, we report the findings over a more clinically pertinent time frame after 1 y to provide information about the longer-term sustainability of any diet-related effects.
METHODS

Design overview
Participants, the study design, and dietary interventions of this single-center, randomized controlled study were previously described (14) . The Commonwealth Scientific Industrial Research Organization Human Research Ethics Committee approved the study, and all participants provided written informed consent. were recruited via a public advertisement. Exclusion criteria were as follows: type 1 diabetes; impaired renal function, proteinuria, or abnormal liver function assessed at screening; any overt endocrinopathy (other than stable treated thyroid disease); history of malignancy; respiratory disease, gastrointestinal disease, or CVD; pregnancy or lactation; and a history of an eating disorder or smoking or having a current eating disorder or current smoking.
Setting and participants
Random assignment and interventions
In a parallel design, participants were block-matched for age, sex, BMI, HbA1c, and diabetes medication by using random varying block sizes before a random computer-generated assignment to either an LC or an HC diet in a 1:1 ratio ( Figure 1 ). Randomization procedures (sequence generation and allocation concealment) were performed by research associates not involved in outcome assessments and the intervention delivery.
At baseline, diet plans were individualized and matched for energy with moderate (w30%) restriction to facilitate weight loss (500-1000-kcal/d deficit; 1357-2143-kcal/d energy prescription) (15) . Energy-content prescriptions remained constant throughout the study to maintain the isocaloric control between diets. The planned macronutrient compositions were, for the LC diet, 14% of total energy from carbohydrate (,50 g/d), 28% of energy as protein, and 58% of energy as total fat (35% monounsaturated fat and 13% polyunsaturated fat) and, for the HC diet, 53% of energy as carbohydrate (emphasis on low-glycemic index foods), 17% of energy as protein, and ,30% of energy as total fat (15% monounsaturated fat and 9% polyunsaturated fat) to reflect conventional dietary guidelines (16) . Both diets limited saturated fat to ,10% of energy. Diets were structured to include specific foods to achieve the targeted macronutrient profile (Supplemental Table 1 ), which were listed in a quantitative food record that participants completed daily. Participants met individually with a dietitian (every 2 wk for 12 wk and monthly thereafter), and key foods (w30% of total energy) that were representative of assigned diet profiles were provided for 12 wk. Thereafter, key foods or vouchers worth 50 Australian dollars were provided on alternate months. Participants undertook, free of charge, 60-min professionally supervised exercise classes in a circuit training format on 3 nonconsecutive days per week that incorporated moderate intensity aerobic and resistance exercise that was consistent with diabetes management guidelines (17) . Attendance records were kept, and participants were encouraged to make up missed sessions. To maximize adherence to study visits, participants were provided with an appointment schedule at the commencement of the study and received appointment reminders (phone calls or text messages) before visits.
Outcomes and follow-up
The primary outcome was the change in HbA1c (Institute of Medical and Veterinary Science Pathology). Secondary outcomes 11 Abbreviations used: CONGA-1, continuous overall net glycemic action of observations 1 h apart; CONGA-4, continuous overall net glycemic action of observations 4 h apart; CRP, C-reactive protein; CVD, cardiovascular disease; FFM, fat-free mass; GV, glycemic variability; HbA1c, glycated hemoglobin; HC, high carbohydrate, low fat; HOMA2-IR, homeostasis model assessment of insulin resistance index 2 to assess insulin resistance; HOMA2-%B, homeostasis model assessment index 2 to assess b cell function; LC, very low carbohydrate, high unsaturated fat, low saturated fat; MAGE, mean amplitude of glycemic excursion; MES, medication effect score; SD Glucose , SD of blood glucose; T2D, type 2 diabetes.
were changes in GV, fasting blood glucose, diabetes medication, weight, blood lipids, and blood pressure. Weight was assessed monthly; all other outcomes were assessed at weeks 0, 24, and 52. Although the diet assignment was discernible by participants and diet interventionists, blinding was maintained for researchers involved in the outcome assessment and data analysis until study completion.
Height was measured with use of a stadiometer (SECA), body mass was measured with use of calibrated electronic scales (Mercury AMZ1), and waist circumference was measured by using a tape measure positioned 3 cm above the iliac crest. Fat mass and fat-free mass (FFM) were determined by using whole-body dual-energy X-ray absorptiometry (Lunar Prodigy; General Electric Corp.). Seated blood pressure was measured by using automated sphygmomanometry (SureSigns VS3; Phillips). Plasma glucose, serum total cholesterol, HDL cholesterol, triglycerides, and C-reactive protein (CRP) were measured with a Roche Hitachi 902 auto-analyzer (Hitachi Science Systems Ltd.) with use of standard enzymatic kits (Roche Diagnostics). LDL cholesterol was calculated by using Friedewald's equation (18) . Plasma insulin concentrations were determined with use of a commercial enzyme immunoassay kit (Mercodia AB). We used the homeostasis model assessment index 2 to assess b cell function (HOMA2-%B) and the homeostasis model assessment of insulin resistance index 2 to assess insulin resistance (HOMA2-IR) (19) .
Diurnal glucose profiles (48 h, consisting of interstitial glucose readings every 5 min) were collected with use of continuous blood glucose monitoring (iPro 2; Medtronic). GV measures computed from continuous glucose monitoring data were as follows: the minimum, maximum, and mean blood glucose; intraday SD of blood glucose (SD Glucose ); mean amplitude of glycemic excursions (MAGEs) (average of blood glucose excursions .1 SD of the mean blood glucose value) (20) ; continuous overall net glycemic action of observations 1 h apart (CONGA-1) and continuous overall net glycemic action of observations 4 h apart (CONGA-4) (SD of differences between observations) (21) ; and glucose range. The MAGEs and continuous overall net glycemic action were computed by using an automated algorithm (22) . The proportion of total time spent in the hypoglycemic range (,3.9 mmol/L), euglycemic range (3.9-10 mmol/L), or hyperglycemic range (.10 mmol/L), as defined by American Diabetes Association glycemic control targets (23), were calculated.
Medications (including doses and schedules) at baseline and changes throughout the study were documented. Changes in diabetes medication requirements were quantified by the antiglycemic medication effect score (MES), which was computed on the basis of the potency and dosage of diabetes medications including insulin (6) . A higher MES corresponded to a higher diabetes medication requirement.
Dietary intake was assessed randomly from 7 consecutive days of daily weighed food records for every 14-d period. Data were analyzed with Foodworks Professional Edition Version 7 software (2012; Xyris Software) to calculate the average quarterly nutrient intake over 52 wk. The ratio of 24-h urinary urea to creatinine (Institute of Medical and Veterinary Science) was assessed as a marker of protein intake (24) . Plasma b-hydroxybutyrate concentrations were assessed monthly as a marker of reduced carbohydrate intake (RANBUT D-3 Hydroxybutyrate kit; Antrim). Physical activity levels were assessed with 7 consecutive days of triaxial accelerometry (GT33+model; ActiGraph) by using predefined validity cutoffs (25) and exercise-session attendance.
Statistical analysis
Data were examined for normality, and the following skewed variables were transformed before analyses: HbA1c (reciprocal transformation); FFM, accelerometry data, insulin, HOMA2-IR, and HOMA2-%B (square-root transformation); and fasting glucose, SD Glucose , the glucose range, MAGEs, CRP, the MES, and b-hydroxybutyrate (logarithmic transformation). Group differences in baseline characteristics and exercise attendance were compared by using independent t tests and chi-square tests for continuous and categorical variables, respectively. The primary analysis was performed by using a random-coefficient analysis with data assumed to be missing at random. The restricted maximum-likelihood, mixed-effects model permitted a variable number of observations for participants, and an unstructured covariance accounted for the correlation between repeated measures over time by allowing the intercept for individuals to vary randomly. The model included all available data from the 115 participants who commenced the study, and changes from weeks 0 to 52 are reported. The model contained the following fixed effects: the main effect for each time-point, diet group assignment, and diet group-by-time point interaction. The proportion of total time spent in the hypoglycemic, hyperglycemic, or euglycemic range was analyzed by using mixed b regression with generalized estimating equations via the GLIMMIX procedure (SAS software, version 9.2; SAS Institute Inc.) (26) . A repeatedmeasures ANOVA with diet as the between-subject factor and time as the within-subject factor was used to assess changes in dietary intake, b-hydroxybutyrate concentrations, and the urinary urea: creatinine excretion ratio between groups. The trial was designed to have 80% power to detect a previously reported 0.7% absolute difference in HbA1c (primary outcome) between diets (6, 7, 27) . Results are presented as estimated marginal means and 95% CIs by using a linear mixed-effects model analysis and were performed with SPSS 20.0 for Windows software (SPSS Inc.), unless otherwise stated. Statistical tests were 2 tailed with significance set at P , 0.05.
RESULTS
Participants
A total of 115 participants (LC-diet group: n = 57; HC-diet group: n = 58) commenced the study. Baseline characteristics did not differ between groups ( Table 1) . Sixteen participants withdrew before the commencement and assignment disclosure (Figure 1 ). After 52 wk, 68% of participants (LC-diet group: n = 41; HC-diet group: n = 37) completed the study ( Table 2) . Attrition rates were comparable between diets (P = 0.51).
Glycemic control and variability
HbA1c and fasting blood glucose were similarly reduced in both groups (P $ 0.10; Table 2 ). Compared with the HC diet, the LC diet produced at least w2-fold greater mean (95% CI) decreases in GV indexes including MAGEs [LC diet: 21. Compared with participants who consumed the HC diet, subjects who consumed the LC diet were more likely to spend a lower proportion of time in the hyperglycemic range (P-time 3 diet = 0.049) with a trend for a greater proportion of time in the euglycemic range (P = 0.07). Both diet groups spent a comparable proportion of time in the hypoglycemic range (P = 0.33)
Medication changes
The LC diet achieved a greater reduction in the antiglycemic MES than did the HC diet (P = 0.02). A greater proportion of LC-diet participants (52%) compared with HC-diet participants (21%) experienced a $20% reduction in the antiglycemic MES (P , 0.01; Table 2 ). For each individual who completed the study, changes in diabetes medication and the total daily dose at baseline and after 52 wk of the dietary interventions are presented in Supplemental Table 2 . Ten participants reduced (LCdiet group: n = 4; HC-diet group: n = 6) and 4 participants increased (LC-diet group: n = 3; HC-diet group: n = 1) their lipid-lowering medications. Twenty-one participants reduced (LC-diet group: n = 13; HC-diet group: n = 8) and 3 participants increased (LC-diet group: n = 2; HC-diet group: n = 1) their antihypertensive medications.
Body weight and composition
Overall, a 9.1% weight loss was achieved ( Figure 3 ) with comparable changes in fat mass, FFM, and waist circumference in both groups (P $ 0.09; Table 2 ).
Blood pressure, lipids, and other CVD risk markers
Compared with the HC diet, the LC diet resulted in greater reductions in triglyceride and increases in HDL cholesterol. Both groups experienced similar reductions in total cholesterol, LDL Total analyzed: n = 115 (LC-diet group: n = 58; HC-diet group: n = 57) for all data unless otherwise stated. To convert mM/L to mg/dL, multiply by 18 (for glucose), 38.7 (for cholesterol), and 88.6 (for TGs). All baseline characteristics were not significantly different between diet groups (P . 0.05) by using the independent samples t test (for continuous variables) or the chi-square test (for categorical variables). CONGA-1, continuous overall net glycemic action of observations 1 h apart; CONGA-4, continuous overall net glycemic action of observations 4 h apart; CRP, C-reactive protein; CVD, cardiovascular disease; DBP, diastolic blood pressure; DPP-4, dipeptidyl-peptidase-4; FFM, fat-free mass; FM, fat mass; GLP-1, glucagon-like peptide-1; HbA1c, glycated hemoglobin; HC, high carbohydrate, low fat; HOMA2-IR, homeostasis model assessment of insulin resistance index 2 to assess insulin resistance; HOMA2-%B, homeostasis model assessment index 2 to assess b cell function; LC, very low carbohydrate, high unsaturated fat, low saturated fat; MAGE, mean amplitude of glycemic excursion; MES, medication effect score; MVPA, moderate to vigorous intensity physical activity; SBP, systolic blood pressure; SD Glucose , SD of blood glucose; TG, triglyceride. Computed from continuous glucose monitoring data. 4 Total analyzed: n = 103 (LC-diet group: n = 52; HC-diet group: n = 51) for insulin, HOMA2-IR, and HOMA2-%B data; 12 participants who were taking insulin medication at baseline were excluded from these analyses. 5 Total analyzed n = 105 (LC-diet group: n = 54; HC-diet group: n = 51) for CRP data; 10 participants with CRP concentrations .10 mg/L at baseline were excluded from these analyses. 6 Computed from accelerometry data.
cholesterol, blood pressure, CRP, insulin, HOMA2-IR, and HOMA2-%B (P $ 0.15; Table 2 ).
Diet and physical activity compliance
Reported dietary intakes were consistent with the planned diets; energy intakes did not differ between groups ( Table 3) . The LC-diet group had lower intakes of carbohydrate and fiber and higher intakes of protein, total fat, saturated fat, monounsaturated fat, polyunsaturated fat, and cholesterol than the HC-diet group did (P , 0.001 for all). Plasma b-hydroxybutyrate concentrations increased more with the LC diet after 4 wk and remained higher over 52 wk than with the HC diet (P-time by diet , 0.001; data not shown). Similarly, the ratio of urinary urea:creatinine excretion increased with the LC diet and remained higher than with the HC diet over 52 wk Total analyzed: n = 115 (LC-diet group: n = 58; HC-diet group: n = 57) for all data unless otherwise stated. To convert mM/L to mg per deciliter, multiply by 18 (for glucose), 38.7 (for cholesterol), and 88.6 (for TGs). Values were determined by using a linear mixed-effects model analysis. P values are for between-group differences over time (time 3 diet interaction). CRP, C-reactive protein; CVD, cardiovascular disease; DBP, diastolic blood pressure; FFM, fat-free mass; FM, fat mass; HbA1c, glycated hemoglobin; HC, high carbohydrate, low fat; HOMA2-IR, homeostasis model assessment of insulin resistance index 2 to assess insulin resistance; HOMA2-%B, homeostasis model assessment index 2 to assess b cell function; LC, very low carbohydrate, high unsaturated fat, low saturated fat; MES, medication effect score; MVPA, moderate to vigorous intensity physical activity; SBP, systolic blood pressure; TG, triglyceride. Mean; 95% CIs in parentheses (all such values). 3 Total analyzed: n = 115 (LC-diet group: n = 58; HC-diet group: n = 57) for continuous glucose monitoring data; the continuous glucose monitoring device did not collect valid data for one LC-diet participant at 24 wk because of poor system connectivity. 4 Total analyzed: n = 106 (LC-diet group: n = 55; HC-diet group: n = 51) for insulin, HOMA2-IR, and HOMA2-%B data; 9 participants who were taking an insulin medication at baseline, 24 wk, and 52 wk or who withdrew before these time points were excluded from these analyses. 5 Total analyzed: n = 112 (LC-diet group: n = 56; HC-diet group: n = 56) for CRP data; 3 participants with CRP concentrations .10 mg/L at baseline, 24 wk, and 52 wk or who withdrew before these time points were excluded from these analyses. 6 Total analyzed: n = 115 for accelerometry data; 2 participants (LC-diet group: n = 1; HC-diet group: n = 1) at 24 wk and 6 participants (LC-diet group: n = 4; HC-diet group: n = 2) at 52 wk who did not meet the validity criteria were excluded from these analyses.
(P-time by diet , 0.01; data not shown), which indicated a lower carbohydrate and higher protein intake in LC-diet participants, respectively.
Mean 6 SD exercise-session attendance was similar between groups (LC diet: 81.2 6 18.0%; HC diet: 77.5 6 21.6%; P = 0.47). Both groups had similar increases in mean activity count and time spent in moderate to vigorous physical activity (P $ 0.24; Table 2 ).
Adverse events
Twenty-one participants (LC-diet group: n = 8; HC-diet group: n = 13) reported musculoskeletal ailments. These ailments were associated with exercise training in 14 participants (LC-diet group: n = 6; HC-diet group: n = 8) that allowed program continuation after recovery. Three participants (LC-diet group: n = 2; HC-diet group: n = 1) reported gastrointestinal disorders (constipation and diverticulitis); one HC-diet participant reported esophageal ulcers with Helicobacter pylori infection; one LC-diet participant had a nonhospitalized hypoglycemia incident; one HCdiet participant was hospitalized for arrhythmia with suspected heart failure; one LC-diet participant and one HC-diet participant were diagnosed with prostate cancer and melanoma, respectively. Other adverse events include nonstudy related workplace injuries . P values are for-between group differences. CONGA-1, continuous overall net glycemic action of observations 1 h apart; CONGA-4, continuous overall net glycemic action of observations 4 h apart; HC, high carbohydrate, low fat; LC, very low carbohydrate, high unsaturated fat, low saturated fat; MAGE, mean amplitude of glycemic excursion; SD Glucose , SD of blood glucose.
FIGURE 3
Estimated mean (95% CI) marginal changes in body weight after 52 wk of consumption of an LC or HC diet on the basis of a linear mixed-effects model (n = 115). For between-group differences, P = 0.18. HC, high carbohydrate, low fat; LC, very low carbohydrate, high unsaturated fat, low saturated fat. in 4 participants (LC-diet group: n = 3; HC-diet group: n = 1); one LC-diet participant was hospitalized for pneumonia; one LC-diet participant was diagnosed with malignant hyperthermia; one HCdiet participant developed an anaphylactic reaction to the influenza vaccine; and one HC-diet participant had a motor vehicle accident.
DISCUSSION
This study showed that hypocaloric, energy-matched LC and HC diets administered as part of a holistic lifestyle-modification program incorporating regular exercise achieved substantial weight loss, improved glycemic control, and reduced CVD risk factors in obese adults with T2D. In addition, compared with the HC diet, the LC diet achieved greater reductions in diabetes medications and enhanced improvements in diurnal blood glucose stability and the lipid profile. These effects were sustained over 1 y, which indicated the durability of the findings over the long term.
Previous studies that compared ad libitum very-low-carbohydrate diets with calorie-restricted HC diets in T2D reported mixed results with some studies reporting greater weight loss after a very-low-carbohydrate diet (11, 28) , and others reporting no differential effect (6) (7) (8) 10 ). In the current study, diets were isocalorically prescribed and achieved comparable weight loss, which suggested that the caloric deficit, independent of the macronutrient composition, is the primary determinant of weight loss. The overall 9.1% weight loss achieved was clinically relevant and associated with an expected 25% reduction in mortality risk (29) , which was comparable with that of (30) and superior to that achieved by many other lifestyle interventions in T2D (2-5 kg) (31, 32) . This marked weight loss could be attributed to the intensity of the lifestyle intervention, which included a detailed diet and exercise prescription administered with regular professional support (33) . Therefore, although the study's highly controlled clinical setting may have limited the generalizability of results to a community setting, the substantial weight loss achieved underscored the importance of comprehensive lifestyle-modification programs for long-term weight loss success. The sustained weight loss achieved promoted substantial reductions in blood pressure, insulin resistance, and inflammation. The blood pressure reductions observed have been associated with clinically significant reductions in risks of diabetes-related complications, CVD, and mortality (34). Reboldi et al. (35) reported risk of stroke decreases by 13% for each 5-mm Hg reduction in systolic blood pressure and by 11.5% for each 2-mm Hg reduction in diastolic blood pressure.
In contrast to previous studies that administered very-lowcarbohydrate diets ad libitum, the current study compared isocaloric LC and HC diets that led to comparable weight loss and HbA1c reductions. These results are consistent with some previous studies (6, (8) (9) (10) . However, other studies have shown greater HbA1c reductions with a very-low-carbohydrate diet (7, 27, 28) that could be explained by differences in energy intakes and weight loss between the very-low-carbohydrate and HC diets examined. The 1% HbA1c reduction achieved in the current study is comparable with the reductions observed in the Look AHEAD (Action for Health in Diabetes) study (from 7.3% to 6.6%) after an intensive lifestyle intervention in T2D (36) . These HbA1c reductions are similar to those observed with monoglycemic and combination noninsulin hypoglycemic agents (37) , and are expected to be associated with marked reductions in diabetes related mortality and complications (38) . Although several randomized controlled trials that targeted HbA1c (,6%) with intensive medical therapy showed no benefit for reducing CVD events or mortality (39) (40) (41) , it is possible this absence of a benefit observed may have been attributed to medication-related side effects, including hypoglycemia, which has been associated with increased mortality risk (42) .
In the current study, although no apparent diet differences in HbA1c were evident, greater reductions in diabetes medications occurred with the LC diet. Compared with the HC diet, the LC diet achieved comparable HbA1c reductions with a significantly greater reduction in diabetes medication requirements, suggesting the achievement of better glycemic control. Because of the progressive nature of T2D, a reduced reliance on pharmacotherapy to achieve glycemic control presents important advantages for long-term diabetes management. These advantages include potential reductions in treatment costs and a reduced likelihood of drug-related side effects including hypoglycemia risk and weight gain with implications for long-term weight-loss maintenance. A health economics analysis was beyond the scope of this trial but should be undertaken in future studies to evaluate the cost effectiveness of the interventions examined. Nevertheless, the current results suggest that lowering HbA1c by a lifestyle modification (diet, exercise, and weight loss) may confer greater health benefits than by intensifying medications through concurrent improvements of other metabolic risk factors and the mitigation of pharmacotherapy-related side effects.
In addition to the diet-related difference in diabetes medications requirements, compared with the HC diet, the LC diet consistently induced at least w2-fold greater reductions across several GV markers, although significance was not achieved for all markers, which was possibly due to the lack of statistical power. Specifically, the LC diet achieved significant, greater effectiveness at mitigating short-term GV assessed by using CONGA-1 and CONGA-4 to achieve a more physiologically stable blood glucose profile. GV (a measure of the amplitude, frequency, and duration of diurnal glucose fluctuations), including postprandial glucose excursions, is emerging as independent risk factors for diabetes complications (12, 13, (43) (44) (45) (46) . Collectively, these results suggest that an LC diet may have greater usefulness for optimizing glycemic control and preventing diabetes complications. However, individuals with uncontrolled diabetes at baseline (HbA1c .11.0%) were excluded from the study, and whether these results are generalizable to these patients requires confirmation.
Similar to previous studies, the LC diet achieved greater reductions in triglycerides and increases in HDL cholesterol than with the HC diet (4, 47) . These results suggests that an LC diet is more effective at improving lipid abnormalities associated with insulin resistance and the metabolic syndrome, which increases CVD risk in T2D (48) . Combined with the substantial weight loss achieved, these consistent blood lipid changes that reflected differences in carbohydrate intake between groups showed the strength of the study to achieve and maintain high dietary adherence throughout the intervention.
In contrast to meta-analyses of previous trials that reported improvements in LDL cholesterol favoring HC compared with very-low-carbohydrate diets (4, 5), the current study showed both diets achieved comparable LDL-cholesterol reductions. This result may have been be attributed to the replacement of carbohydrate with unsaturated fats in the LC diet (49, 50) and was consistent with previous observations in carbohydrate-restricted diets that showed greater reductions in LDL cholesterol with lower compared with higher saturated fat intakes (51) . These results highlight the clinical significance of the unique fatty acid profile of the LC diet used in the current study that was similarly low in saturated fat as in the HC diet, therefore distinguishing it from very-low-carbohydrate diets that have been investigated in previous studies that were typically high in saturated fat. Consequently, an LC diet that is high in unsaturated fat and low in saturated fat diet may provide the optimal combination for improving glycemic control and CVD risk reduction in T2D. Furthermore, a separate line of evidence has suggested a verylow-carbohydrate diet alters the LDL subclass profile by preferentially increasing large, buoyant LDL particles that, unlike small, dense LDL particles, are less atherogenic (51) . This evidence suggests that CVD risk assessment should consider both the quantity and quality of LDL subfractions (52) . Therefore, an additional evaluation of the effects on clinical endpoints such as CV events and diabetes complications will provide greater understanding of the therapeutic potential of LC diets.
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